Development and Analysis of the Standard for Management of Antineoplastic Drugs Use in Clinical
10.3870/j.issn.1004-0781.2024.08.009
- VernacularTitle:《抗肿瘤药物临床应用管理标准》制订与解析
- Author:
Guanmin ZHANG
1
;
Yanhua ZHANG
;
Jiancun ZHEN
;
Ying CHEN
;
Wei ZHANG
;
Ling JIANG
;
Jianqing WANG
;
Xiaoyang LU
;
Qianzhou LYU
;
Zhiqing ZHANG
;
Daihua LIU
;
Jiaxi XI
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科,恶性肿瘤发病机制及转化研究教育部重点实验室,北京 100142
- Keywords:
Antineoplastic drugs;
Standard formulation;
Institutional pharmacy administration
- From:
Herald of Medicine
2024;43(8):1226-1229
- CountryChina
- Language:Chinese
-
Abstract:
Antineoplastic drugs refer to the drugs that act at the cellular and molecular levels to inhibit tumor growth or eliminate tumors through pathways such as cell killing,immune regulation,and endocrine regulation.Antineoplastic drugs generally including chemotherapeutic drugs,molecular targeted therapeutic drugs,immunotherapeutic drugs,and endocrine therapeutic drugs.The management and rational application of antineoplastic drugs in medical institutions are related to the safety of patient treatment.The standard for management of antineoplastic drugs use in clinical is compiled by the Pharmaceutical Affairs Committee of China Hospital Association,which specification requirements 18 key elements in the organizational management and system,medication management,drug monitoring and evaluation of antineoplastic drug management in healthcare institutions.This standard is applicable to all levels and types of healthcare institutions carrying out oncology diagnosis and treatment.This paper describes the methodology and basic content of the standard,hoping to providing a reference for medical institutions to carry out relevant work.
